STOCK TITAN
  1. Home
  2. Sec-filings
  3. PLSE
  4. [Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity

Pulse Biosciences COO buys 2,025 shares

Pulse Biosciences’ chief operating officer bought 2,025 PLSE shares in open-market trades over two days during an open trading window.

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. (PLSE) Chief Operating Officer Liane Rae Teplitsky reported open-market purchases of company common stock. On August 31, 2026, she purchased 1,024 shares at a weighted average price of about $48.80 per share, in trades executed between $48.76 and $48.80. On September 1, 2026, she purchased an additional 1,001 shares at $49.95 per share. All trades were made in an open trading window under the company’s Insider Trading Policy, and no Rule 10b5-1 trading plan is reported.

Positive

  • None.

Negative

  • None.
Insider Teplitsky Liane Rae
Role Chief Operating Officer
Bought 2,025 shs ($100K)
Type Security Shares Price Value
Purchase Common Stock F1, F2, F4 1,001 $49.95 $50K
Purchase Common Stock F1, F2, F3 1,024 $48.80 $50K
Holdings After Transaction: Common Stock — 4,095 shares (Direct)
Footnotes (4)
  1. F1. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
  2. F2. The purchase of fractional shares has been rounded down to the nearest whole number.
  3. F3. Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share.
  4. F4. Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price.
Shares purchased August 31, 2026 1,024 shares Open-market purchase of PLSE common stock by the COO
Weighted average purchase price August 31, 2026 $48.80 per share Executed in a range of $48.76 to $48.80 per share
Shares purchased September 1, 2026 1,001 shares Open-market purchase of PLSE common stock by the COO
Purchase price September 1, 2026 $49.95 per share Open-market purchase of PLSE common stock by the COO
Total shares purchased 2,025 shares Sum of both reported open-market purchases
open trading window regulatory
"The shares were purchased during an open trading window under the Company's Insider Trading Policy"
A designated period when company executives, directors and certain employees are permitted to buy or sell their employer’s stock under the company’s trading policy because material information has been disclosed. Think of it like scheduled store hours after a big delivery: it reduces the risk of trading on secret information, and investors watch insider activity during these windows as a signal of how those closest to the business view its prospects.
Insider Trading Policy regulatory
"purchased during an open trading window under the Company's Insider Trading Policy"
A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.
weighted average sale price financial
"Represents the weighted average sale price of shares purchased in a series of open market transactions"
broker-dealer financial
"through a trade order executed by a broker-dealer"
A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.

FAQ

What insider transactions did PLSE’s chief operating officer report?
Liane Rae Teplitsky reported two open-market purchases of Pulse Biosciences common stock, buying 1,024 shares on August 31, 2026 and 1,001 shares on September 1, 2026.

How many PLSE shares did the COO buy in total in this Form 4?
Across both reported transactions, the chief operating officer purchased a total of 2,025 shares of Pulse Biosciences common stock in open-market trades.

At what prices were the PLSE shares purchased by the COO?
On August 31, 2026, the COO’s open-market purchases were executed at prices ranging from $48.76 to $48.80 per share, with a reported weighted average price of about $48.80. On September 1, 2026, she purchased shares at $49.95 per share.

Were the PLSE insider purchases made under a Rule 10b5-1 trading plan?
No. The document-level Rule 10b5-1 checkbox is not checked, and a footnote states the shares were purchased during an open trading window under the company’s Insider Trading Policy.

Were the PLSE insider purchases direct or through an entity?
Both reported transactions list the ownership type as direct, indicating the chief operating officer directly holds the purchased Pulse Biosciences common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Teplitsky Liane Rae
(Last)(First)(Middle)
C/O PULSE BIOSCIENCES, INC.
3957 POINT EDEN WAY
(Street)
HAYWARD CALIFORNIA 94545
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026P(1)1,024(2)A$48.8(3)3,094(2)D
Common Stock09/01/2026P(1)1,001(2)A$49.95(4)4,095(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
2. The purchase of fractional shares has been rounded down to the nearest whole number.
3. Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share.
4. Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price.
/s/ Kenneth B. Stratton09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR